This finding has attractive therapeutic implications, as a small molecule inhibitor of HIF2α has been recently approved for patients with von‐Hippel Lindau disease and is in clinical testing for other tumor types (Wallace et al, 2016; Courtney et al, 2018; Renfrow et al, 2018; Hasanov & Jonasch, 2021). Here, EPAS1 is linked to neoplasm.